文献速递乳腺癌

相对剂量强度作为乳腺癌辅助化疗日常临床实践的质量与预后替代指标

Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
PubMed 文献 · Eur J Cancer · 2017-05-08

该研究纳入2008至2013年在圣安东尼医院接受乳腺癌辅助化疗的605例患者,约10%出现相对剂量强度(RDI)<85%。预测因素包括年龄、发热性中性粒细胞减少及紫杉类III/IV级过敏反应;FEC-D方案发热性中性粒细胞减少发生率为24%,超过欧洲癌症研究与治疗组织初级G-CSF预防阈值。中位随访38个月未发现RDI与(无病)生存的关系,除疾病分期外肥胖也是不良结局预测因素。

要点

  • 605例患者中约10%出现RDI<85%,预测因素为年龄、发热性中性粒细胞减少及紫杉类过敏反应。
  • FEC-D方案发热性中性粒细胞减少发生率为24%,超过EORTC初级G-CSF预防阈值。
  • 中位随访38个月未发现RDI与(无病)生存的关系,但需更长随访。

核心结论

  • RDI<85%可由患者年龄、发热性中性粒细胞减少及紫杉类过敏反应预测。
  • FEC-D治疗中发热性中性粒细胞减少的发生率提示多西他赛治疗后应进行G-CSF初级预防。
  • 未发现RDI与(无病)生存的关系,但需要更长随访。

研究设计与样本

  • 研究纳入2008年至2013年在圣安东尼医院接受乳腺癌辅助化疗的所有患者,共605例。
  • 计算每种化疗药物及整个化疗方案的RDI,研究RDI<85%的发生率、原因及其对预后的影响。

主要发现

  • 605例患者中约10%出现RDI<85%。
  • 预测因素包括年龄、发热性中性粒细胞减少发作及对紫杉类的III或IV级过敏反应。
  • 其他不良事件如周围神经病变未影响RDI。
  • FEC-D方案中发热性中性粒细胞减少的发生率为24%,超过欧洲癌症研究与治疗组织设定的初级G-CSF预防阈值。
  • 中位随访38个月,未发现RDI与(无病)生存的关系;除疾病分期外,肥胖是不良结局的预测因素。

关键数值与推荐

  • 荷兰指南推荐RDI至少85%以实现最佳治疗。
  • FEC-D方案发热性中性粒细胞减少发生率24%,超过EORTC初级G-CSF预防阈值。

临床怎么用

  • 作者结论指出,FEC-D治疗中发热性中性粒细胞减少的发生率提示多西他赛治疗后应进行G-CSF初级预防。
  • 原文未据此给出其他推荐。

局限性

  • 需要更长随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Adjuvant chemotherapy treatment of women with breast cancer is frequently complicated by toxic side-effects, resulting in dose reduction and delay. In Dutch guidelines, a relative dose intensity (RDI) of at least 85% is recommended for optimal treatment. The aim was to investigate predictors of low RDI and its effect on prognosis. METHODS: All patients treated in the St. Antonius Hospital with adjuvant chemotherapy for breast cancer between 2008 and 2013 were included (N = 605). RDI was calculated for each single chemotherapeutic agent and for chemotherapy regimens in total. Incidence and causes of RDI <85% were studied, as well as the effect of RDI on prognosis. RESULTS: About 10% of 605 patients had RDIs <85%. Predictive factors included age, episodes of febrile neutropenia and grade III or IV hypersensitivity reaction to taxanes. Other adverse events, such as peripheral neuropathy, did not affect RDI. The incidence of febrile neutropenia in the 5-fluorouracil, epirubicin, cyclofosfamide, docetaxel (FEC-D) protocol was 24% and therefore was above the threshold set by the European Organisation for Research and Treatment of Cancer for primary granulocyte colony-stimulating factor (G-CSF) prophylaxis. No relationship between RDI and (disease-free) survival was found with a median follow-up of 38 months. Apart from the stage of disease, obesity is a predictor of poor outcome. CONCLUSIONS: RDI <85% is predicted by patients' age, febrile neutropenia and hypersensitivity reactions to taxanes. The incidence of febrile neutropenia in FEC-D treatment indicates primary prophylaxis with G-CSF following docetaxel treatment. No relationship was found between RDI and (disease-free) survival, but longer follow-up is needed.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schraa SJ, Frerichs KA, Agterof MJ, et al. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice. Eur J Cancer. 2017. PMID: 28494406. doi:10.1016/j.ejca.2017.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。